Strata Critical Medical, Inc. (SRTA)
NASDAQ: SRTA · Real-Time Price · USD
6.15
+0.02 (0.33%)
May 26, 2026, 10:37 AM EDT - Market open
Strata Critical Medical Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Strata Critical Medical stock has a consensus rating of "Strong Buy" and an average price target of $9.13. The average 1-year stock price forecast is 48.46% higher than the current stock price, while the lowest is $8.00 (+30.08%) and the highest is $11.5 (+86.99%).
Price Target: $9.13 (+48.46%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Strata Critical Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Nov '25 | Dec '25 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 1 | 2 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 1 | 2 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ladenburg Thalmann & Co. | Ladenburg Thalmann & Co. | Buy Reiterates $12 | Buy | Reiterates | $12 | +86.99% | May 7, 2026 |
| Lake Street | Lake Street | Buy Reiterates $8 | Buy | Reiterates | $8 | +30.08% | May 6, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 6, 2026 |
| B. Riley Securities | B. Riley Securities | Buy Initiates $8 | Buy | Initiates | $8 | +30.08% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
280.02M
from 197.14M
Increased by 42.04%
Revenue Next Year
297.94M
from 280.02M
Increased by 6.40%
EPS This Year
0.05
from 0.50
Decreased by -90.68%
EPS Next Year
0.14
from 0.05
Increased by 193.48%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 288.8M | 308.5M | ||
| Avg | 280.0M | 297.9M | ||
| Low | 268.4M | 283.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 46.5% | 10.2% | ||
| Avg | 42.0% | 6.4% | ||
| Low | 36.2% | 1.1% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | 0.30 | 0.45 |
| Avg | 0.05 | 0.14 |
| Low | -0.08 | -0.01 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | -40.0% | 851.1% |
| Avg | -90.7% | 193.5% |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.